Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia


22 Nov 2020


e-Poster Display Session


Tumour Site

Breast Cancer


Anna Tai


Annals of Oncology (2020) 31 (suppl_6): S1257-S1269. 10.1016/annonc/annonc353


A.Y.P. Tai1, M. Singh2, J. Binko3, K. Lilly4, S. Chang5, S. Bowles6, M. Alam7

Author affiliations

  • 1 Clinical Oncology, Queen Elizabeth Hospital, Yau Ma Tei - Hong Kong/CN
  • 2 Pfizer Medical Affairs, Pfizer Inc, N/A - Quarry Bay/HK
  • 3 Pfizer Medical Affairs, Pfizer Inc, Melbourne/AU
  • 4 Project Management, Parexel International Pty Ltd, North Ryde, NSW/AU
  • 5 Biostatistics, Parexel International Pty Ltd, Taipei/TW
  • 6 Account Services, Intouch Solutions, New York/US
  • 7 Pfizer Medical Affairs, Pfizer Inc, Sydney/AU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 69TiP


The incidence of breast cancer in Asia is rising. Recent advances in hormone receptor (HR) positive and human epidermal growth factor receptor negative advanced breast cancer (aBC) includes introduction of the CDK 4/6 inhibitors. Palbociclib was the first drug in this class to be introduced in Asia and is approved for use in aBC in combination with aromatase inhibitors (P+AI) as initial endocrine based therapy in postmenopausal women or with fulvestrant (P+F) in women with disease progression following endocrine therapy. Globally, there has been evaluations in the real world setting for palbociclib. However, data published for Asian patients in this setting remains scarce.

Trial design

Study Design: A prospective, observational, non-interventional, multi-centre study. A smartphone-based mobile application to collect patient-reported outcomes (PROs) associated with aBC and its treatment on Palbociclib has been developed. The impact of aBC and associated treatment of symptoms, functioning and quality of life (QOL) as reported by patients will be studied. Clinical data on therapy management, occurrence of neutropenia and any association between neutropenia, quality of life and PROs will also be captured. Eligibility Criteria: Women with HR+/HER2– aBC receiving P+AI or P+F as per approved indication in their country. Aims and Objectives: Primary objectives are to assess and describe clinical and PROs in eligible patient population. 12-Item ‘Short Form Health Survey’ & ‘Center for Epidemiological Studies Depression Scale’ would be used. The study will also document changes in therapy as well as the incidence, severity, and duration of neutropenia through data recorded from patient’s medical records. Statistical Methods: For the purpose of this study, analyses will generally be descriptive in nature and will be conducted using SAS statistical software Present Accrual and Target Accrual: Approximately 100 patients from up to 12 sites within 4 Asian countries (Taiwan, India, Malaysia and Hong Kong) will be enrolled. Study duration will be approximately 12 months assuming 6 months of recruitment. The study is open in all 4 participating countries with 7 patients recruited so far.

Clinical trial identification

Legal entity responsible for the study

Pfizer Inc.


Pfizer Inc.


M. Singh, J. Binko, M. Alam: Shareholder/Stockholder/Stock options, Full/Part-time employment: Pfizer Inc. K. Lilly, S. Chang: Full/Part-time employment: Parexel International Pty Ltd. S. Bowles: Full/Part-time employment: Intouch Solutions. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.